SETD2 Blocking Peptide

Huntington's disease (HD), a neurodegenerative disorder characterized by loss of striatal neurons, is caused by an expansion of a polyglutamine tract in the HD protein huntingtin. This gene encodes a protein belonging to a class of huntingtin interacting proteins characterized by WW motifs. This protein is a histone methyltransferase that is specific for lysine-36 of histone H3, and methylation of this residue is associated with active chromatin. This protein also contains a novel transcriptional activation domain and has been found associated with hyperphosphorylated RNA polymerase II. [provided by RefSeq, Aug 2008]

SETD2: Histone methyltransferase that methylates 'Lys-36' of histone H3. H3 'Lys-36' methylation represents a specific tag for epigenetic transcriptional activation. Probably plays a role in chromatin structure modulation during elongation via its interaction with hyperphosphorylated POLR2A. Binds DNA at promoters. May also act as a transcription activator that binds to promoters. Binds to the promoters of adenovirus 12 E1A gene in case of infection, possibly leading to regulate its expression. Belongs to the histone-lysine methyltransferase family. SET2 subfamily. 3 isoforms of the human protein are produced by alternative splicing.

Protein type: Amino Acid Metabolism - lysine degradation; Methyltransferase, protein lysine; EC 2.1.1.43; Methyltransferase

Chromosomal Location of Human Ortholog: 3p21.31

Cellular Component: nucleoplasm; chromosome

Molecular Function: protein binding; histone-lysine N-methyltransferase activity

Biological Process: pericardium development; establishment and/or maintenance of chromatin architecture; stem cell development; mismatch repair; regulation of transcription, DNA-dependent; mesoderm morphogenesis; forebrain development; neural tube closure; RNA elongation from RNA polymerase II promoter; embryonic cranial skeleton morphogenesis; morphogenesis of a branching structure; angiogenesis